# Tesamorelin Research: The Pivotal Trials, the Mechanism, and the 2026 Meta-Analysis > Tesamorelin reduced visceral fat 15.2%, raised IGF-1 81%, and pooled to a -27.71 cm2 VAT change across five RCTs. The mechanism and the trial record, organized study by study and cited. Mechanism, the two pivotal Phase 3 trials, the hepatic-fat data, and the 2026 meta-analysis — with every quantitative result attributed to its source. ## The short version The tesamorelin research record is unusually deep for a peptide of its class, because the drug went through full FDA approval. The strongest evidence sits in two large trials of adults living with HIV who had abnormal belly-fat buildup: a daily 2 mg injection shrank visceral fat (the deep fat around the organs) by about 15% over six months and kept it down through a year [1][2]. Raising the body's own growth hormone and IGF-1 (a growth signal from the liver) is how it works [4]. A 2026 pooled analysis of five trials confirmed the visceral-fat effect [13]. All of this was measured in HIV patients. ## Mechanism: GHRH receptor to visceral lipolysis Tesamorelin acts on the anterior pituitary. It binds the GHRH receptor on somatotroph cells, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade and driving CREB-mediated transcription of the growth-hormone gene plus secretory-granule exocytosis [4]. The secreted GH signals hepatic JAK2/STAT5 pathways to synthesize IGF-1, and GH and IGF-1 jointly activate hormone-sensitive lipase to break down stored triglyceride, preferentially in visceral fat [6]. The healthy-men study isolates this chain cleanly. In 13 men, 2 mg/day for two weeks raised mean overnight GH by 0.5 ug/L (P=0.004) and increased IGF-1 by 181 ug/L (P<0.0001), while fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) were unchanged [4]. Because it amplifies the body's own pulsatile GH rhythm rather than supplying exogenous hormone, the metabolic profile differs from recombinant growth hormone [6]. ## The pivotal Phase 3 trials in HIV lipodystrophy The registration evidence rests on two pivotal trials. In the 26-week Phase 3 RCT of 412 HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% while placebo increased it by 5.0%; triglycerides fell 50 mg/dL (versus +9 mg/dL on placebo) and IGF-1 rose 81.0% [1]. The 52-week program (2 mg/day, n=273, versus placebo n=137) sustained the visceral-fat reduction at -18% (P<0.001 versus baseline). Visceral fat reaccumulated on discontinuation, and changes in glucose parameters over 52 weeks were not clinically significant [2]. A pooled analysis of both Phase 3 trials (806 ART-treated patients) confirmed that visceral adipose tissue decreased significantly versus placebo and was maintained through 52 weeks, alongside improved body-image distress scores and lipids, with subcutaneous fat preserved and no clinically meaningful glucose changes [7]. ## Visceral fat, hepatic fat, and fat quality A 6-month JAMA RCT in 50 antiretroviral-treated HIV adults sharpened the picture. Tesamorelin 2 mg/day produced a treatment effect of -42 cm2 in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) [3]. The liver benefit appears mediated by visceral-fat loss and GH/IGF-1 signaling rather than a direct hepatic drug effect. A later analysis found the drug also improves fat quality, not just quantity: over 26 weeks it raised visceral-fat density on CT by +6.2 HU and subcutaneous-fat density by +4.0 HU versus placebo (both P<0.0001), independent of changes in fat amount [10]. Inflammatory-marker work in the same population showed reduced tissue plasminogen activator antigen and modestly increased adiponectin, with the changes correlating to the degree of visceral-fat reduction — pointing to visceral fat as the mediating mechanism [9]. ## Who responds, and the 2026 meta-analysis A pooled predictor analysis of two Phase 3 RCTs (543 tesamorelin versus 263 placebo) found the odds of reducing visceral fat below 140 cm2 were 3.9-fold greater with tesamorelin (95% CI 2.03-7.44); baseline metabolic syndrome, triglycerides above 1.7 mmol/L, and white race predicted response, with no predictors identifiable at 3 months [11]. A post-hoc analysis showed the visceral-fat and waist-circumference reduction was comparable regardless of dorsocervical-fat status (P=0.657) [12]. The most recent synthesis is a 2026 meta-analysis of five RCTs in HIV-associated lipodystrophy. It found tesamorelin reduced visceral adipose tissue by a mean difference of -27.71 cm2 (95% CI -38.37 to -17.06; P<0.001), trunk fat by -1.18 kg, and hepatic fat fraction by -4.28%, while increasing lean body mass by +1.42 kg (all P<0.001), without serious adverse events [13]. Two 2026 narrative reviews place the compound in context: an orthopaedic primer notes it is approved for HIV-associated lipodystrophy with no supporting orthopaedic evidence [14], and a sports-medicine review groups it among investigational growth-hormone-axis secretagogues with uncertain safety profiles and broad antidoping restrictions [15]. The [reported safety signals](/side-effects) are summarized separately, and the full [references and citations](/references) list every study. ## What the record does not yet show The strength of the tesamorelin evidence is also its boundary. Every efficacy figure above was measured in HIV-positive adults on antiretroviral therapy [1][2][7]; the corpus contains no completed large-scale fat-loss RCT in a general, non-HIV population. The healthy-men study confirmed the GH/IGF-1 mechanism but measured hormones, not body fat [4]. Generalizing the visceral-fat result beyond HIV is mechanistically plausible but not established [14]. Two further gaps are worth stating plainly. Long-term oncologic-safety data are limited despite no excess malignancy signal over 52 weeks, which is why active malignancy remains a labeled contraindication [2][4]. And the benefit was contingent on continued dosing: visceral fat reaccumulated within weeks of stopping [2]. The record is deep where it is deep — HIV lipodystrophy, 26 to 52 weeks, 2 mg/day — and explicitly thin everywhere else. --- Tesamorelin read down to its numbers — one GHRH(1-44) analogue, the visceral-fat and IGF-1 figures left standing alone against the studies that measured them, and the approved-for-HIV-lipodystrophy line drawn exactly where the off-label field begins; an editorial reference plate, not a clinic, a vendor, or a prescription.